版本:
中国

BRIEF-Spring Bank Pharma provides positive mid-stage data on Hep B drug

May 23 Spring Bank Pharmaceuticals Inc

* Spring bank pharmaceuticals announces top-line results from the initial cohort of the phase 2a segment of the achieve trial, a global phase 2 clinical trial for chronic hepatitis b virus (hbv)

* Spring bank - sb 9200 shows favorable safety profile and antiviral activity against hbv dna and hbsag with initial low dose monotherapy of 25mg

* Spring bank pharmaceuticals inc - overall safety profile of sb 9200 was favorable, and over 12-week study, no serious adverse events were observed Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐